Trials / Recruiting
RecruitingNCT06399757
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Apollo Therapeutics Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
Conditions
- Colorectal Cancer
- Cholangiocarcinoma
- Appendiceal Adenocarcinoma
- Pancreatic Adenocarcinoma
- Gastric Adenocarcinoma
- Endometrial Adenocarcinoma
- Triple Negative Breast Cancer
- Ovarian Cancer
- Prostate Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APL-5125 | APL-5125 is an oral drug (capsule) taken daily in 28-day cycles |
Timeline
- Start date
- 2024-06-18
- Primary completion
- 2027-04-01
- Completion
- 2027-05-01
- First posted
- 2024-05-06
- Last updated
- 2026-01-07
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06399757. Inclusion in this directory is not an endorsement.